Three experts – Catherine Guettier, Sheeba Irshad, and Anthony M. Magliocco – reflect on Owkin’s international survey on the opportunities and challenges for digital pathology and AI solutions
Medica recently participated in the new UK NEQAS CPT Digital Pathology Pilot Scheme and scored ‘excellent’!
f you had asked Flora Abilova 20 years ago where she saw herself, she might have pictured a courtroom, arguing cases with the sharp precision of a seasoned lawyer. Or maybe a C-suite office, a woman in a power suit making high-stakes decisions for a multinational corporation.
Aiforia Technologies Plc, a provider of cutting-edge AI-assisted medical software solutions, announced today that it has successfully obtained the In Vitro Diagnostic Regulation (IVDR) certification. At the same time, the company launches three new CE-IVD marked AI models for breast and prostate cancer diagnostics.
In a new study, researchers at Henan University and Fourth Military Medical University in China developed a new artificial intelligence (AI)-driven pathomics approach to enhance the ability of CDKN2A to predict prognosis in patients with head and neck squamous cell carcinoma (HNSCC).
Bicêtre Hospital is a pioneer in the integration of artificial intelligence in pathological anatomy, illustrating the promising future of this technology in the medical field.
The year 2016 witnessed not just a victory of artificial intelligence, but a powerful revelation about its nature. As technical experts and gaming aficionados watched the world's best Go players face AlphaGo, a single, unexpected move reverberated far beyond the 19x19 grid. This was "Move 37," a moment that exposed the profound, almost human-like strategic capacity of AI, and in doing so, offered a lens through which to understand AI's transformative potential across diverse domains – including, crucially, our own fields of pathology and oncology.
HER2 grading is a key factor in the diagnosis and treatment of breast cancer. It determines eligibility for targeted therapies that can block tumor growth effectively. This article explores traditional methods for determining HER2 status, the challenges faced by pathologists, and the contribution of artificial intelligence (AI) in enhancing the accuracy and reproducibility of diagnosis.
Paige, a leader in next-generation AI technology, today announced an expansion of Paige PanCancer Detect, the first AI application capable of identifying cancer across a wide range of tissue and organ types. Originally launched in early 2024 with the ability to help pathologists detect cancer in over 17 different tissues, Paige PanCancer Detect capabilities have now extended to more than 40 tissue and organ types.
This Source LDPath's webinar discusses the biology and mechanism of action of MAF gene leading to these high impact events in the patient pathway. Further it provides biological explanation why the original Phase III trials on the use of bisphosphonates were inconclusive.
